A fluorescence immunoassay for detection of immune complexes bound to solid-phase Clq was developed. The method was standardized by using human aggregated immunoglobulin G (IgG) to simulate immune complexes. A linear relationship existed between the concentrations of the aggregated IgG standards and the resulting fluorescent intensity. The method was found to be reproducible and capable of detecting as little as 10 ,g of aggregated IgG per ml of heatinactivated human serum. Antigen-antibody complexes prepared in vitro were detectable from equivalence to moderate antigen excess. Endogenous serum Clq inhibited the binding of aggregated IgG to solid-phase Clq. Pretreatment of test sera with EDTA was ineffective in eliminating this competitive effect. Heating the sera at 56°C alleviated, but did not abolish, interference of endogenous Clq. Elevated levels of immune complexes were detectable in sera from seven of nine patients with systemic lupus erythematosus, provided the samples were heat inactivated before testing. Heparin and DNA were also found to interfere with the detection of aggregated IgG added to human serum. Assay values were falsely decreased due to competitive inhibition by these anions. Lipopolysaccharides from a variety of bacterial preparations produced no detectable interference. A comparative study was conducted on samples that had previously been tested by fluid-phase Clq-binding radioimmunoassay. The two methods were concordant in assigning normal or elevated levels of immune complexes in 70% of the samples tested. This solid-phase fluorescence immunoassay is proposed as a possible alternative to radioimmunoassay for the detection of circulating immune complexes.
Numerous non-antigen-specific methods for the detection of immune complexes have been described (12, 15) . Many of these assays utilize the ability of antigen-antibody complexes to combine with the complement component Clq and have achieved widespread use. The majority of Clq-binding assays use radio-labeled components to quantitate immune complexes (22, 26) . Such radioimmunological methods are extremely sensitive for detection of biologically important substances, but hazards exist in the handling and disposal of radioactive materials. Recent advances in fluoroimmunoassay (FIA) indicate that fluorescent labels are suitable substitutes for radiolabels in many immunoassays (17, 20) .
We have developed a fluorescence assay for the detection of immune complexes bound to solid-phase Clq. The method has been adapted from the FIAX system described originally by International Diagnostic Technology (IDT) of Santa Clara, Calif. Clq is adsorbed to the surface of the IDT StiQ sampler, which is then incubated with the diluted test sample. Antigenantibody complexes present in the serum bind to Clq via the Fc portion of the immunoglobulin in the complex. After washing, the bound components are then incubated with fluorescein-labeled anti-immunoglobulin G (IgG). Nonreactive substances are washed away, and the remaining fluorescence bound to the solid phase is measured in the FIAX fluorometer. We propose that FIA is an alternative to radioimmunoassay (RIA) for the detection of immune complexes and thus eliminates the use of hazardous radioisotopes.
MATERIALS AND METHODS
Aggregated IgG (AGG). Human IgG (Gammagee; Merck, Sharp & Dohme, West Point, Pa.) was diluted to a concentration of 10 mg/ml in phosphate-buffered saline (PBS), pH 7.2. The preparation was aggregated by heating for 20 min at 63°C and then centrifuged at 1,500 x g for 20 min to remove insoluble aggregates.
Research, Boston, Mass., was diluted to a concentration of 50 ,g/ml in PBS. Thirty microliters of the diluted Clq was placed on the cellulose disk of each sampler, using a hand-held pipetter. The samplers were refrigerated overnight in the moist chamber.
Fluorescent-antibody reagent. Purified F(ab')2 goat anti-human immunoglobulin conjugated with fluorescein isothiocyanate (FITC) was purchased from Kallestad Laboratories, Chaska, Minn. The antiserum was diluted to a concentration of 8 ,ug/ml in PBS containing 0.125% bovine serum albumin (BSA).
Reaction buffer and wash buffer. PBS, 0.05 M, containing 0.1% Tween 20 and 0.5% BSA, pH 6.4 (PBS-BSA-Tw), was used as sample diluent and initial wash solution for solid-phase components.
Immune complex assay. Assays were carried out in glass tubes (12 165 ,000 x g to remove soluble aggregates. Goat anti-human IgG was purchased from Meloy Laboratories (Springfield, Va.), and the specific antibody content was provided by the company. IgG-anti-IgG complexes were prepared by incubating a constant amount of goat antihuman IgG with increasing amounts of monomeric human IgG for 1 h at 37°C followed by a 48-h incubation at 4°C. The precipitin curve was determined (9) , and the antigen/antibody ratio at equivalence was found to be 1:2.5. Immune complexes were prepared at four concentrations of goat anti-human IgG: 20, 50, 100, and 500 ,ug/ml. Increasing amounts of human IgG were added to constant amounts of antibody to produce complexes ranging from 8 times antibody excess to 15 times antigen excess as compared with the equivalence ratio. Both the antigen and the antibody were diluted in PBS and incubated together for 1 h at 37°C followed by a 48-h incubation at 4°C. After centrifugation for 20 min at 1,000 x g, the supernatants were tested in the immune complex assay.
Preparation of tetanus toxoid-antitetanus toxoid complexes. Purified tetanus toxoid was purchased from Lederle Laboratories, Pearl River, N.Y. The undiluted preparation was dialyzed against PBS for 24 h at 4°C. Protein content as determined by the method of Lowry et al. (13) was 165 ,ug/ml. The immunoglobulin fraction of a human antitetanus antiserum (Hypertet) was purchased from Cutter Laboratories, Berkeley, Calif. This antiserum was diluted in PBS and centrifuged for 60 min at 130,000 x g in a Beckman LS-65 ultracentrifuge to remove aggregated immunoglobulins. Soluble immune complexes were prepared by using a 1:10 and 1:20 dilution of the tetanus antisera. Increasing amounts of toxoid (10 to 165 ,ug/ml) were added to tubes containing constant amounts of the antibody-containing fraction. Both the antigen and the antibody were diluted in PBS and incubated together for 1 h at 37°C followed by incubation for 4 days at 4°C. The tubes were then centrifuged for 30 min at 1,000 x g, and the supernatants were tested for the presence of antigen or antibody by Ouchterlony analysis and visually by the Swift-Wilson-Lancefield capillary tube test (14) . Equivalence was determined as that tube in which neither antigen nor antibody could be detected. The supernatants were then tested in the immune complex assay.
Potential interfering substances. Double-stranded (ds) DNA (calf thymus DNA, type I) was purchased from Sigma Chemical Co., St. Louis, Mo. Singlestranded (ss) DNA was prepared by heating the native DNA at 100°C for 10 min at a concentration of 0.5 mg/ ml in PBS, followed by immediate cooling in an ice bath. Liquaemin sodium heparin was purchased from Organon, Inc., West Orange, N.J.
Lipopolysaccharides (LPS) from the following bacterial preparations were purchased from Sigma: phenol extract of Salmonella minnesota, S. typhosa, S. typhimurium, and Escherichia coli O111:B4; trichloroacetic acid extract of S. enteritidis, S. typhosa, and S. typhimurium. The trichloroacetic acid extracts of S.
VOL. 15, 1982 on December Assay of complexes formed in vitro. IgG-antiIgG complexes were prepared by using human monomeric IgG and goat anti-human IgG antibody. We recognized that quantitation of these prepared complexes would be based on the binding of FITC-anti-human IgG to the antigen (human IgG) bound in the complex. Therefore, in addition to verifying the detection of antigenantibody complexes, we assessed the adaptability of this assay as an antigen-specific method. Controls which contained antibody or antigen alone were included. The goat anti-human IgG antibody alone produced fluorescence equivalent to that of the buffer blank. The fluorescence of the human monomeric IgG alone was minimal at all concentrations tested (Fig. 2) . Soluble complexes were detected from equivalence to five times antigen excess at all antibody concentrations. Complexes in antibody excess were not detected.
Soluble tetanus toxoid-antitoxoid complexes were tested in a similar manner, and controls were included which contained antigen or antibody alone. The tetanus toxoid antigen alone produced fluorescence no higher than that of the buffer blank, and fluorescence of the antitetanus antisera was minimal (Fig. 3) . Soluble complexes were detected from equivalence to three times antigen excess. Again, complexes in antibody excess were not detected. Fig. 4 . Addition of EDTA to NHS either before or after the addition of AGG did not eliminate the inhibitory effect of endogenous serum Clq. After incubation of AGG with NHS or NHS/EDTA, heating at 56°C partially restored the binding of AGG with SPClq. It is apparent that heating did not destroy all complex-bound Clq but did allow for significantly greater binding. Detection of AGG added to NHS-56°C was essentially the same when the sample was diluted in PBS or EDTA, suggesting that EDTA itself was not adversely affecting the reaction. The Clq-binding activity of the negative controls is shown for each sample. Heating NHS at 56°C resulted in only a slight increase in Clq binding in this assay. Therefore, it appeared that the increased detection of AGG after heat inactivation of positive samples was due to the release of bound endogenous Clq rather than nonspecific aggregation of immunoglobulin.
Effect of 56°C heat inactivation on the detection of immune complexes in sera of SLE patients and normal controls. Serum samples from nine systemic lupus erythematosus (SLE) patients and nine normal individuals were tested in the, immune complex assay before and after heating for 30 min at 56°C (Fig. 5) . All sera from patients with SLE contained significant levels of antibody to ds DNA (>25 ng of DNA bound/25 ,ul of serum) when tested by RIA. A mean increase of 6.0 ,ug equivalents (eq) of AGG/ml was observed in the sera of normal individuals after heat treatment. The mean increase after heating sera of SLE patients was 16.4 jig eq of AGG/ml. This increase was more than 2 standard deviations above the mean increase seen in the normal controls, suggesting that the increased Clqbinding activity was not due merely to nonspecific aggregation alone.
Subsequently, 54 human serum samples obtained from apparently healthy donors were heated for 30 min at 56°C and assayed in triplicate. The mean value obtained was 15.98, and 1 standard deviation was 5.85. To determine the upper limit of normal, the data were ranked from low to high, and the 95% confidence value was calculated. The normal range was found to be 1 to 25 jig eq of AGG/ml.
Detection of AGG in the presence of NHS. The accuracy and precision of this method were studied by adding AGG to heat-inactivated NHS. Controls were prepared to contain approximately 10, 50, and 150 ,ug of AGG/ml and were tested in triplicate in 10 separate runs. Serum without added aggregates was included VOL. 15, 1982 on with each determination, and the fluorescence of this negative sample was subtracted from that of the serum containing AGG. There was good agreement between the measured and expected concentrations of AGG at all levels, and the results were reproducible (Table 1) .
Intra-assay precision was assessed by preparing controls to contain 25, 100, and 150 ,ug of AGG/ml. (ii) ds and ss DNA. Increasing concentrations of ds DNA (1.0 to 300 pug/ml) or ss DNA (0.5 to 100 ,ug/ml) were added to portions of serum containing 50 ,ug of AGG/ml. As little as 5 ,ug of ss DNA and 30 ,ug of ds DNA per ml interfered in this assay (Fig. 6 ).
(iii) Heparin. Increasing concentrations of heparin (1.0 to 200 U/ml) were added to sera containing 70 or 150 ,ug of AGG/ml. Inhibition was detectable at heparin concentrations of 5 U/ ml (Fig. 7) . Extremely high concentrations of heparin were required to totally abolish the binding of AGG to SP-Clq. (Table 3) . enough to activate complement but are not readily recognized and cleared from the circulation by phagocytic cells (25) . Therefore, these complexes may have the greatest pathogenic hat FIA is a potential, and we have demonstrated that they Lantitation of are detectable with the FIA. Iq. The FIAX The flexibility of this method was demonstratcostly due to ed by assaying preformed IgG-anti-IgG immune e solid-phase complexes. Quantitation of these complexes quires a spe-was based on the binding of FITC-anti-IgG to late the sam-the antigen (human IgG) bound in the complex. described in This immunoassay may thus be adapted to an table to other antigen-specific method by using the appropriate fluorescein-labeled antibody. Similarly, other classes or subclasses of antibodies bound in immune complexes may be identified by altering the FITC-labeled probe accordingly.
Endogenous serum Clq was found to inhibit the binding of immune complexes and AGG to SP-Clq. This is not surprising, since most Clqbinding assays are similarly affected (19, 21) . Pretreatment of test sera with EDTA is a technique used by others (8, 26) to eliminate endogenous Clq interference, but was found to be ineffective in our assay. EDTA chelates calcium necessary for integrity of the Clqrs complex. However, calcium is not needed for binding of Clq with complexed immunoglobulin. Apparently, addition of EDTA in this solid-phase assay will not "unmask" immune complexes which have bound complement in vivo. Heating the sera at 56°C before testing under the described conditions was found to be essential, even though we recognize that there are problems created by this treatment. Heat inactivation of the test sera after addition of AGG partially destroyed the inhibitory effect of endogenous Clq. However, the levels of detection were somewhat lower than when AGG was added to preheated sera. These findings are consistent with those of Teppo and Wager (24) , who reported that free Clq is more heat labile than Clq bound to immune complexes. Therefore, the sensitivity of the FIA for detecting low levels of immune complexes which have fixed complement in vivo may be somewhat diminished.
Heating sera at 56°C before detecting immune complexes has often been criticized. Some investigators have found false-positive results due to heat-induced aggregation of serum immunoglobulins (5) . Other studies have shown that heating test sera may decrease the ability of preexisting complexes to bind exogenous Clq (19, 26) . When sera from normal individuals were tested in the FIA, no significant evidence on December 18, 2017 by guest http://jcm.asm.org/ Downloaded from for heat-induced aggregation was observed. However, when sera from patients with SLE were tested, this assay was able to detect complexes in seven of nine patients if the sera were heat inactivated before testing. The increased levels of complex detection were more than 2 standard deviations greater than that seen with normal sera and thus could not be explained by nonspecific aggregation. No decrease in Clq binding was observed in any of the samples after heating, which indicates that complexes were not destroyed by this treatment.
The specificity of this assay was investigated by competitive inhibition studies. Since this method uses a fluorescein-labeled anti-IgG probe, non-immunoglobulin substances that bind Clq will not produce false-positive results. However, if test sera contain antigen-antibody complexes as well as certain other Clq-reactive substances, assay values may be falsely decreased due to competitive inhibition.
Although LPS has been shown to activate Clq (4), concentrations as high as 200 ,ug/ml did not interfere with the detection of AGG.
Single-stranded DNA and, to a lesser extent, ds DNA were found to inhibit binding of AGG with SP-Clq. This was probably the result of a firm ionic interaction between the positively charged Clq molecule and these anions (3). In addition, the strength of binding to Clq may be dependent on molecular size (10). High-molecular-weight substances such as DNA may be capable of interacting with several Clq-binding sites simultaneously or may simply induce steric hindrance. The reaction conditions of this assay included low-ionic-strength buffer to obtain maximal sensitivity for complexes of IgG. Most anionic substances also bind most strongly with Clq under this condition (5, 10) . Possibly, the inhibitory capacity of anionic substances may be decreased by performing this assay at higher ionic strength.
Undoubtedly, interference by such anions is a limitation to the specificity of this method, but it is one that is shared by most immune complex assays using Clq. One major difference, however, is that in other Clq-binding assays, with the exception of the solid-phase method described by Hay et al. (8) , the interference by DNA may be manifested as falsely elevated levels of immune complexes (12) . Therefore, these techniques might not discriminate between free DNA antigen alone and immune complexes containing DNA. Of the existing methodologies using Clq, it is possible that only direct Clqbinding assays using labeled anti-immunoglobulin can accurately distinguish clinically significant immune complexes from DNA. This suggestion may partially explain the finding of Abrass et al. (1) that the solid-phase Clq-binding RIA correlated better than the fluid-phase Clq assay with clinical activity in SLE. However, the fact that low levels of complexes may go undetected in the presence of DNA cannot be ignored. Detailed clinical studies were not conducted in our laboratory, but sera from seven of nine SLE patients tested were shown to have elevated levels of immune complexes. These results are consistent with those found in extensive studies of SLE (1, 16, 18) . In pathological conditions, antigen-antibody ratios may change daily (7) . Interpretation of immune complex assay results must necessarily take all these factors into consideration.
Heparin was also found to inhibit the binding of AGG to SP-Clq. As with DNA, the effect of this polyanion is probably related to negatively charged groups interacting with the cationic Clq (2) . Competitive inhibition studies demonstrated that approximately 5 U of heparin per ml of serum was required to interfere with the detection of AGG. The primary significance of this finding is that samples to be tested by this method must not be collected in heparinized tubes. Although it has not been verified, sera from patients undergoing carefully controlled heparin therapy may still be suitable for testing by this method. Patients receiving therapeutic heparin doses generally have plasma levels of 0.1 to 0.5 U of heparin/ml (6, 23) . However, heparin absorption and excretion rates vary for each individual, and again, potential interference must be considered when this Clq-binding assay is used for detection of immune complexes.
A comparative study was performed on 68 samples that had previously been tested by fluidphase Clq-binding RIA. The two methods were concordant in assigning normal or elevated levels of immune complexes in 70% of the samples tested. Our data indicate that the fluorescence method is subject to the same types of problems common to most Clq-binding assays but suggest that the technique may be as reliable in quantitation of immune complexes as other assays currently available. Investigations are in progress to find alternatives to heat inactivation and to minimize the effects of interfering substances. However, the primary significance of this report is that FIA presents an alternative to RIA for the detection of immune complexes. 
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